Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 4
2005 2
2006 3
2008 4
2009 4
2010 4
2011 10
2012 12
2013 13
2014 9
2015 9
2016 23
2017 23
2018 24
2019 20
2020 13
2021 23
2022 22
2023 24
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

197 results

Results by year

Filters applied: . Clear all
Page 1
Risk Factors for the Development of Psoriasis.
Kamiya K, Kishimoto M, Sugai J, Komine M, Ohtsuki M. Kamiya K, et al. Among authors: ohtsuki m. Int J Mol Sci. 2019 Sep 5;20(18):4347. doi: 10.3390/ijms20184347. Int J Mol Sci. 2019. PMID: 31491865 Free PMC article. Review.
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, Papp KA, Sofen H, Puig L, Foley P, Ohtsuki M, Flack M, Geng Z, Gu Y, Valdes JM, Thompson EHZ, Bachelez H. Gordon KB, et al. Among authors: ohtsuki m. Lancet. 2018 Aug 25;392(10148):650-661. doi: 10.1016/S0140-6736(18)31713-6. Epub 2018 Aug 7. Lancet. 2018. PMID: 30097359 Clinical Trial.
Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up.
Papp KA, Blauvelt A, Puig L, Ohtsuki M, Beissert S, Gooderham M, Amin AZ, Liu J, Wu T, Azam T, Stakias V, Espaillat R, Sinvhal R, Soliman AM, Pang Y, Chen MM, Lebwohl MG. Papp KA, et al. Among authors: ohtsuki m. J Am Acad Dermatol. 2023 Dec;89(6):1149-1158. doi: 10.1016/j.jaad.2023.07.1024. Epub 2023 Aug 6. J Am Acad Dermatol. 2023. PMID: 37553030 Free article. Clinical Trial.
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.
Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, Reich K, Amato D, Ball SG, Braun DK, Cameron GS, Erickson J, Konrad RJ, Muram TM, Nickoloff BJ, Osuntokun OO, Secrest RJ, Zhao F, Mallbris L, Leonardi CL; UNCOVER-1 Study Group; UNCOVER-2 Study Group; UNCOVER-3 Study Group. Gordon KB, et al. Among authors: ohtsuki m. N Engl J Med. 2016 Jul 28;375(4):345-56. doi: 10.1056/NEJMoa1512711. Epub 2016 Jun 8. N Engl J Med. 2016. PMID: 27299809 Free article. Clinical Trial.
Efficacy and safety of the selective TYK2 inhibitor, deucravacitinib, in Japanese patients with moderate to severe plaque psoriasis: Subgroup analysis of a randomized, double-blind, placebo-controlled, global phase 3 trial.
Imafuku S, Tada Y, Hippeli L, Banerjee S, Morita A, Ohtsuki M. Imafuku S, et al. Among authors: ohtsuki m. J Dermatol. 2023 May;50(5):588-595. doi: 10.1111/1346-8138.16740. Epub 2023 Mar 7. J Dermatol. 2023. PMID: 36882942 Clinical Trial.
TLR7/8 stress response drives histiocytosis in SLC29A3 disorders.
Shibata T, Sato R, Taoka M, Saitoh SI, Komine M, Yamaguchi K, Goyama S, Motoi Y, Kitaura J, Izawa K, Yamauchi Y, Tsukamoto Y, Ichinohe T, Fujita E, Hiranuma R, Fukui R, Furukawa Y, Kitamura T, Takai T, Tojo A, Ohtsuki M, Ohto U, Shimizu T, Ozawa M, Yoshida N, Isobe T, Latz E, Mukai K, Taguchi T, Hemmi H, Akira S, Miyake K. Shibata T, et al. Among authors: ohtsuki m. J Exp Med. 2023 Sep 4;220(9):e20230054. doi: 10.1084/jem.20230054. Epub 2023 Jul 18. J Exp Med. 2023. PMID: 37462944 Free PMC article.
The ability of biomarkers to assess the severity of atopic dermatitis.
Nakahara T, Onozuka D, Nunomura S, Saeki H, Takenaka M, Matsumoto M, Kataoka Y, Fujimoto R, Kaneko S, Morita E, Tanaka A, Saito R, Okano T, Miyagaki T, Aoki N, Nakajima K, Ichiyama S, Kido-Nakahara M, Tonomura K, Nakagawa Y, Tamagawa-Mineoka R, Masuda K, Takeichi T, Akiyama M, Ishiuji Y, Katsuta M, Kinoshita Y, Tateishi C, Yamamoto A, Morita A, Matsuda-Hirose H, Hatano Y, Kawasaki H, Fukushima-Nomura A, Ohtsuki M, Kamiya K, Kabata Y, Abe R, Mitsui H, Kawamura T, Tsuji G, Katoh N, Furue M, Izuhara K. Nakahara T, et al. Among authors: ohtsuki m. J Allergy Clin Immunol Glob. 2023 Sep 27;3(1):100175. doi: 10.1016/j.jacig.2023.100175. eCollection 2024 Feb. J Allergy Clin Immunol Glob. 2023. PMID: 37915726 Free PMC article.
197 results